Company Encyclopedia
View More
name
CT ENTERPRISE
03839.HK
Chia Tai Enterprises International Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment products portfolio consists of CTC premix and CTC hydrochloride, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brand names. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of motorcycle carburetors and automotive parts for automobile and motorcycle manufacturers.
35.95 B
03839.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
A
Agricultural Products and ServicesIndustry
Industry Ranking1/11
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.24%B
    • Profit Margin5.36%C
    • Gross Margin16.61%D
  • Growth ScoreA
    • Revenue YoY154.24%A
    • Net Profit YoY551.48%A
    • Total Assets YoY14.17%B
    • Net Assets YoY11.95%B
  • Cash ScoreA
    • Cash Flow Margin1864.81%A
    • OCF YoY154.24%A
  • Operating ScoreA
    • Turnover1.36A
  • Debt ScoreB
    • Gearing Ratio34.40%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" CT ENTERPRISE's net profit for the first nine months was USD 23.54 million, an increase of 4.5 times

    CT ENTERPRISE announced its performance for the first nine months ending in September, with revenue of USD 431 million, an increase of 152.4% year-on-year; gross profit of USD 59.59 million, up 91.8%. It recorded a net profit of USD 23.54 million, a growth of 452.3%

    AASTOCKS·
    HK
    03839
    -1.98%
    AASTOCKS·
    HK
    03839
    -1.98%

    Understanding the Market | CT ENTERPRISE fell over 7%, expecting third-quarter net profit to drop to approximately USD 6.5 million

    CT ENTERPRISE fell over 7%, as of the time of publication, down 7.07% to HKD 7.62, with a trading volume of HKD 5.4218 million. In terms of news, on the evening of October 21, CT ENTERPRISE announced that it expects to achieve an unaudited consolidated profit attributable to shareholders of approximately USD 23.5 million for the nine months ending September 30, 2025, compared to USD 4.3 million in the same period last year, a year-on-year increase of 4.47 times. The growth in profit is mainly due to a significant increase in revenue, reflecting the successful implementation of key strategies for developing major customer sales. However, due to the slowdown in China's livestock industry, the demand for the company's veterinary pharmaceutical products is also expected to decrease starting from the third quarter of 2025. The group's unaudited quarterly consolidated profit attributable to shareholders for the three months ending September 30, 2025, is expected to drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025

    Zhitong·
    HK
    03839
    -1.98%
    Zhitong·
    HK
    03839
    -1.98%

    "Profit Alert" CT ENTERPRISE forecasts a doubling of profit to USD 23.5 million for the first nine months

    CT ENTERPRISE announced a profit warning, expecting a profit of approximately USD 23.5 million for the nine months ending in September, compared to USD 4.3 million recorded in the same period last year. The profit growth is mainly due to the group's successful implementation of key strategies for developing major customer sales, resulting in a significant increase in revenue

    AASTOCKS·
    HK
    03839
    -1.98%
    AASTOCKS·
    HK
    03839
    -1.98%

    CT ENTERPRISE announced a positive profit forecast, expecting a comprehensive profit attributable to shareholders of approximately USD 23.5 million for the first three quarters, an increase compared to the same period last year

    CT ENTERPRISE expects that the consolidated profit attributable to shareholders for the first three quarters ending September 30, 2025, will be approximately USD 23.5 million, a significant increase year-on-year, mainly due to revenue growth and the successful implementation of sales strategies for major clients. However, due to the slowdown in China's livestock industry, the demand for veterinary pharmaceutical products has decreased in the third quarter of 2025, and it is expected that the consolidated profit attributable to shareholders for that quarter will drop to approximately USD 6.5 million

    Zhitong·
    HK
    03839
    -1.98%
    Zhitong·
    HK
    03839
    -1.98%

    Understanding the Market | CT ENTERPRISE rose over 8% again as Muyuan Group and Charoen Pokphand Group reached a strategic cooperation. The company is a producer of gold powder under Charoen Pokphand

    CT ENTERPRISE rose more than 8% again, with a cumulative increase of over 570% this year. As of the time of writing, it rose 8.79% to HKD 10.02, with a transaction volume of HKD 15.4734 million. In terms of news, on August 28, Muyuan Group and Charoen Pokphand Group officially signed a strategic cooperation agreement at the True Building in Bangkok, Thailand. This collaboration, seen as a partnership between the world's first and third largest pig farming giants, will involve comprehensive cooperation in areas such as strategic planning, business integration, and global layout, promoting deep collaboration in feed, pig farming, slaughtering and food processing, talent, and capital. Public information shows that CT ENTERPRISE is a subsidiary of Charoen Pokphand Group and is one of the world's leading producers of chlortetracycline. Huaxin Securities previously pointed out in a research report that looking at the global veterinary chlortetracycline market, China's Jinhe Biological and Charoen Pokphand Biological together account for over 90% of global production capacity, presenting a duopoly competition pattern. Financial reports show that the company's net profit in the first half of the year increased by 768.36% year-on-year, mainly due to the significant growth of the group's biochemical business, which focuses on animal health pharmaceutical products and chlortetracycline

    Zhitong·
    HK
    03839
    -1.98%
    Zhitong·
    HK
    03839
    -1.98%
    © 2025 Longbridge｜Disclaimer